1. Home
  2. GANX vs TYGO Comparison

GANX vs TYGO Comparison

Compare GANX & TYGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GANX
  • TYGO
  • Stock Information
  • Founded
  • GANX 2017
  • TYGO 2007
  • Country
  • GANX United States
  • TYGO United States
  • Employees
  • GANX N/A
  • TYGO N/A
  • Industry
  • GANX Biotechnology: Pharmaceutical Preparations
  • TYGO Semiconductors
  • Sector
  • GANX Health Care
  • TYGO Technology
  • Exchange
  • GANX Nasdaq
  • TYGO Nasdaq
  • Market Cap
  • GANX 69.0M
  • TYGO 82.5M
  • IPO Year
  • GANX 2021
  • TYGO N/A
  • Fundamental
  • Price
  • GANX $1.58
  • TYGO $1.77
  • Analyst Decision
  • GANX Strong Buy
  • TYGO Strong Buy
  • Analyst Count
  • GANX 5
  • TYGO 1
  • Target Price
  • GANX $8.20
  • TYGO $6.00
  • AVG Volume (30 Days)
  • GANX 526.2K
  • TYGO 365.9K
  • Earning Date
  • GANX 11-13-2025
  • TYGO 11-05-2025
  • Dividend Yield
  • GANX N/A
  • TYGO N/A
  • EPS Growth
  • GANX N/A
  • TYGO N/A
  • EPS
  • GANX N/A
  • TYGO N/A
  • Revenue
  • GANX N/A
  • TYGO $74,405,000.00
  • Revenue This Year
  • GANX N/A
  • TYGO $94.76
  • Revenue Next Year
  • GANX N/A
  • TYGO $19.11
  • P/E Ratio
  • GANX N/A
  • TYGO N/A
  • Revenue Growth
  • GANX N/A
  • TYGO 52.31
  • 52 Week Low
  • GANX $1.36
  • TYGO $0.58
  • 52 Week High
  • GANX $3.19
  • TYGO $1.90
  • Technical
  • Relative Strength Index (RSI)
  • GANX 39.85
  • TYGO 70.16
  • Support Level
  • GANX $1.55
  • TYGO $1.58
  • Resistance Level
  • GANX $1.78
  • TYGO $1.45
  • Average True Range (ATR)
  • GANX 0.13
  • TYGO 0.12
  • MACD
  • GANX -0.03
  • TYGO 0.02
  • Stochastic Oscillator
  • GANX 6.00
  • TYGO 76.99

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

About TYGO Tigo Energy Inc.

Tigo Energy Inc designs solar power conversion and storage products that provide customers with more choice and flexibility. Its mission is to deliver smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Geographically the company generates revenue from EMEA, Americas, and APAC.

Share on Social Networks: